Merck & Company Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
Merck & Company Inc Forecast
Merck & Company Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 34.0% a year, a typical one-standard-deviation range is 139.32–153.34 over a week, 131.97–160.69 over a month and 96.60–196.06 over a year. (Signals as of 1 Nov 2026.)
Merck & Company Inc Price Chart
Merck & Company Inc Factors
YoY +1,054.5%
YoY +42.0%
YoY +71.8%
YoY +254.4%
YoY +45.4%
YoY −24.0%
YoY −91.3%
YoY −30.7%
YoY +48.8%
YoY +90.5%
YoY +343.1%
YoY −18.6%
YoY −20.8%
YoY −82.3%
YoY +50.1%
YoY −42.9%
YoY +0.3%
Merck & Company Inc fundamentals: income statement, balance sheet & cash flow
Merck & Company Inc reported revenue of $64.93bn and net income of $18.25bn in FY2025, the year ended 31 December 2025 — revenue up 1.2% and net income up 6.6% on the prior year. Free cash flow was $12.36bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 64.93 | 64.17 | 60.12 | 59.28 | 48.70 |
| Cost of revenue | 18.20 | 15.19 | 16.13 | 17.41 | 13.63 |
| Gross profit | 46.73 | 48.98 | 43.99 | 41.87 | 35.08 |
| Research & development | 12.51 | 17.94 | 30.53 | 13.55 | 12.25 |
| Operating income | 23.49 | 20.22 | 2.95 | 18.28 | 13.20 |
| EBITDA | 28.26 | 25.71 | 6.91 | 21.32 | 17.90 |
| Interest expense | 1.36 | 1.27 | 1.15 | 0.96 | 0.81 |
| Pre-tax income | 21.07 | 19.94 | 1.89 | 16.44 | 13.88 |
| Income tax | 2.80 | 2.80 | 1.51 | 1.92 | 1.52 |
| Net income | 18.25 | 17.12 | 0.37 | 14.52 | 13.05 |
Download Merck & Company Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.MRK.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Merck & Company Inc
Recent MacroFinance research reports referencing Merck & Company Inc, newest first.
Merck & Company Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Merck & Company Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Merck & Company Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Merck & Company Inc (United States)
Merck & Company Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Merck & Company Inc
Frequently asked questions
What is Merck & Company Inc?
What is the latest Merck & Company Inc price?
Is Merck & Company Inc in an uptrend?
How volatile is Merck & Company Inc?
What factors affect Merck & Company Inc?
Which trading strategies trade Merck & Company Inc?
How are Merck & Company Inc returns analysed?
Where can I download free Merck & Company Inc historical data?
Free Merck & Company Inc historical data (last 10 years)
Browse or instantly download the last 10 years of Merck & Company Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.MRK.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 133.72 |
| 2026-11-19 | 132.81 |
| 2026-11-18 | 137.78 |
| 2026-11-17 | 143.37 |
| 2026-11-16 | 144.46 |
| 2026-11-13 | 147.76 |
| 2026-11-12 | 146.95 |
| 2026-11-11 | 147.18 |
| 2026-11-10 | 148.05 |
| 2026-11-09 | 148.76 |
About this stock
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.